Kellie J Goodlet, Pharm.D., BCPS, BCIDP
Associate Professor
Pharmacy Practice
RESEARCH INTERESTS
Dr. Kellie J. Goodlet conducts research relating to the optimization of antimicrobials and associated therapies in clinical infectious diseases practice. In addition to her collaborations with colleagues at Midwestern University and St. Joseph's Hospital and Medical Center, Dr. Goodlet also offers an Advanced Pharmacy Practice Experience (APPE) rotation which allows third year pharmacy students to participate in infectious diseases research.
Research Interests
Antimicrobial Stewardship: Antimicrobial stewardship involves promoting the minimal necessary antimicrobial use to improve patient outcomes, decrease microbial resistance and adverse effects, and reduce costs. Stewardship principles include treating only infected patients using the least broad-spectrum agents possible, for the shortest effective duration. Rapid de-escalation of broad-spectrum antimicrobials and "diagnostic stewardship" are additional focuses.
Infection Management among Patients Living with Immunodeficiency: Solid organ transplant recipients and other highly immunocompromised populations are at risk for infection with organisms rarely seen among immune competent persons, for which there exists a paucity of data.
Multi-Drug Resistance: Antimicrobial resistance is a global healthcare concern. Patients infected with MDR/XDR organisms face limited treatment options. Additionally, different resistance mechanisms/genotypes often dictate therapy. Antibiotic optimization strategies, including multi-model antibiotic administration, dose-optimization, combination therapy, and utilization of novel antimicrobials may result in successful eradication of infection.
Antimicrobial Safety: Even among well-tolerated antimicrobial classes, significant adverse effects, including potential selection of multi-drug resistant organisms and increased infection risk, are possible. Conversely, for many antimicrobials, the risk and magnitude of adverse reactions is overstated, leading clinicians to overlook potentially beneficial therapies. Rational assessments of the risks and benefits of antimicrobials are needed to inform optimal antimicrobial selection.
Research Interests
Antimicrobial Stewardship: Antimicrobial stewardship involves promoting the minimal necessary antimicrobial use to improve patient outcomes, decrease microbial resistance and adverse effects, and reduce costs. Stewardship principles include treating only infected patients using the least broad-spectrum agents possible, for the shortest effective duration. Rapid de-escalation of broad-spectrum antimicrobials and "diagnostic stewardship" are additional focuses.
Infection Management among Patients Living with Immunodeficiency: Solid organ transplant recipients and other highly immunocompromised populations are at risk for infection with organisms rarely seen among immune competent persons, for which there exists a paucity of data.
Multi-Drug Resistance: Antimicrobial resistance is a global healthcare concern. Patients infected with MDR/XDR organisms face limited treatment options. Additionally, different resistance mechanisms/genotypes often dictate therapy. Antibiotic optimization strategies, including multi-model antibiotic administration, dose-optimization, combination therapy, and utilization of novel antimicrobials may result in successful eradication of infection.
Antimicrobial Safety: Even among well-tolerated antimicrobial classes, significant adverse effects, including potential selection of multi-drug resistant organisms and increased infection risk, are possible. Conversely, for many antimicrobials, the risk and magnitude of adverse reactions is overstated, leading clinicians to overlook potentially beneficial therapies. Rational assessments of the risks and benefits of antimicrobials are needed to inform optimal antimicrobial selection.